Evidence map›Paper›PMID 25625901›Full record

ReviewAgeing research reviews2015

Resveratrol supplementation: Where are we now and where should we go?

Marta G Novelle, Devin Wahl, Carlos Diéguez, Michel Bernier, Rafael de Cabo

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Ageing research reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03313869 (Effects of a Cocktail XXS-2A/Omega-3 on Insulin Sensitivity and Oxidative Stress During a 20-day Period of Physical Inactivity), which is not on this map. Cited by 111 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03313869 nacompletednot on this map

Effects of a Cocktail XXS-2A/Omega-3 on Insulin Sensitivity and Oxidative Stress During a 20-day Period of Physical Inactivity: a Controlled, Randomized Pilot Study on 20 Healthy Men

TypeinterventionalSponsorCentre National d'Etudes SpatialesRan2015 to 2015Enrolled20ConditionsMetabolic Disturbance, Glucose Intolerance, Physical Inactivity, Glucose Metabolism DisordersArmsXXS-2A + Omega-3 + Vitamin E + Selenium, control diet
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 235 citations in OpenAlex.

  1. Interventions that prolong multidimensional healthspan in humans: a systematic review of randomized controlled trials.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Marta G NovelleTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Devin WahlTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Carlos DiéguezResearch Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Michel BernierTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Rafael de CaboTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA. Electronic address: decabora@grc.nia.nih.gov.
National Institute on Aging · USUniversidade de Santiago de Compostela · ES

Funding

Aging Intervention ProgramZIAAG000363 · NIA · NATIONAL INSTITUTE ON AGING · PI DE CABO, RAFAEL · 2009 to 2025
$9.0M
Calorie restriction and agingZIAAG000368 · NIA · NATIONAL INSTITUTE ON AGING · PI DE CABO, RAFAEL · 2009 to 2025
$6.9M
Calorie restriction and agingZ01AG000368 · NIA · NATIONAL INSTITUTE ON AGING · PI DE CABO, RAFAEL · 2005 to 2008
$1.4M
Intramural NIH HHS Z01 AG000368Intramural NIH HHS ZIA AG000363
6 · The paper itself

Abstract

Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.

Indexed as

Dietary SupplementsAgingAnimalsAnti-Inflammatory Agents, Non-SteroidalChronic DiseaseClinical Trials as TopicExerciseHumansResveratrolStilbenesAnti-Inflammatory Agents, Non-SteroidalResveratrolStilbenesBioavailabilityClinical trialsMetabolismResveratrolTranslational research

Identifiers

PMID25625901
PMCPMC5835393
OpenAlexW1986877767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.